CCP was established in 1981 with a registered capital of 100 million yuan, covering an area of 52 mu and a total construction area of 63,000 square meters.
CCP is a national designated second-class psychotropic drug manufacturer. It currently holds approvals for psychotropic drugs such as phenobarbital tablets, hydrocodone-acetaminophen extended-release tablets, and clobazam tablets. The company's product portfolio also includes drugs for oncology, cardiovascular, neurological, respiratory, and ophthalmic systems. It currently operates production lines for tablets, capsules, oral solutions, topical solutions, ointments, and eye drops, with additional lines for hormone-based ointments, ampoule injections, and vial injections under construction.
CCP firmly believes that technology is the core of corporate development, and R&D is the driving force behind the company's growth. The company's R&D team currently consists of over 40 members, with annual R&D investments covering no fewer than 10 product varieties.
CCP emphasizes social responsibility. Since 2016, it has been donating lunch funds to children in rural mountainous area kindergartens and elementary schools, and conducts three regular visits annually to provide care and warmth to elderly residents in mountainous nursing homes.
CCP with its excellent and stable quality, outstanding service, and an enterprise culture of honesty and trustworthiness, sincerely collaborates with you to advance the development of the global pharmaceutical and healthcare industry.
